Alston & Bird’s Food, Drug & Device/FDA Group helped advise Fresenius Medical Care North America in an agreement by Fresenius Medical Care AG & Co., the world’s largest provider of dialysis products and services, to acquire NxStage Medical, Inc., a leading home dialysis device maker. The Alston & Bird team provided assistance with U.S. Food and Drug Administration and related regulatory due diligence as part of the transaction, which is valued at approximately $2 billion.
NxStage produces products aimed at the treatment of end-stage renal disease and acute kidney failure. The company, which is headquartered in Lawrence, MA, and listed on the Nasdaq, posted revenues of $366 million in 2016.
The Alston & Bird regulatory team advising on the transaction was led by partner Julie Tibbets, working closely with associate Justin Mann, senior associate Brendan Carroll, and attorney Caitlin Hosmer.